The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

1. Billings, L.K.
2. Agner, B.F.R.
3. Altuntas, Y.
4. Grøn, R.
5. Halladin, N.
6. Klonoff, D.C.
7. Tentolouris, N.
8. Jódar, E.